---
schema_version: "secwatch.filing_event.v1"
accession: "0001082554-23-000033"
form_type: "8-K"
ticker: "UTHR"
cik: "0001082554"
company_name: "UNITED THERAPEUTICS Corp"
filed_at: "2023-11-01T23:59:59+00:00"
generated_at: "2026-06-09T01:58:20.855138+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# United Therapeutics Q3 revenue $609.4M (+18% YoY), net income $267.6M

## Summary
- Total revenues $609.4M (+18% YoY); net income $267.6M ($5.38 diluted EPS) vs $239.3M ($4.91) Q3 2022.
- Tyvaso DPI sales $205.1M (+225%) drove total Tyvaso $325.8M (+26%); nebulized Tyvaso declined 38% to $120.7M.
- Remodulin $131.1M (+15%), Orenitram $92.0M (+5%), Unituxin $51.3M (+11%).
- R&D expense $84.7M (+28%) from TETON fibrosis studies and organ manufacturing; SG&A $127.6M (+30%).
- CEO cites record quarterly revenue; pipeline data expected in 2025; management reaffirms ~$4B annual run rate.

## SEC filing metadata
- accession: 0001082554-23-000033
- form_type: 8-K
- ticker: UTHR
- cik: 0001082554
- company_name: UNITED THERAPEUTICS Corp
- filed_at: 2023-11-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1082554/000108255423000033/0001082554-23-000033-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1082554/000108255423000033/uthr-20231101.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001082554-23-000033
- JSON: https://secwatch.observer/filing/0001082554-23-000033.json
- Plain text: https://secwatch.observer/filing/0001082554-23-000033.txt

## Key facts
- Earnings Releases
  UNITED THERAPEUTICS Corp reported the quarter ended September 30, 2023 results: revenue $609.4 million, net income $267.6 million, EPS $5.38 per diluted share.
  - Period: the quarter ended September 30, 2023
  - Revenue: $609.4 million
  - Net income: $267.6 million
  - EPS: $5.38 per diluted share
  - Result: reported results
  source text: United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, today announced its financial results for the quarter ended September 30, 2023. Total revenues in the third quarter of 2023 grew 18% year-over-year to $609.4 million, compared to $516.0 million in the third quarter of 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1082554/000108255423000033/0001082554-23-000033-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.